Effect of Gastrogenic Microbiota in FD

Launched by NANFANG HOSPITAL, SOUTHERN MEDICAL UNIVERSITY · Jan 6, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how probiotics, which are beneficial bacteria found in certain foods and supplements, can help people with Functional Dyspepsia (FD). FD is a condition that causes discomfort in the upper stomach, like pain, bloating, and feeling full quickly after eating. The researchers want to see if taking these specific probiotics from the stomach can improve symptoms compared to a placebo, which is a harmless pill that looks like the treatment but doesn't contain any active ingredients.

To participate in this study, you need to be an adult between 18 and 70 years old who has experienced symptoms like stomach pain or bloating and meets specific criteria for FD. You'll also need to have tested negative for Helicobacter pylori, a type of bacteria that can cause stomach issues. If you join the trial, you'll take either the probiotics or the placebo for a certain period, and researchers will monitor your symptoms and health. It's important to know that some people, such as those with certain medical conditions or who are taking specific medications, may not be eligible to participate. The trial is currently recruiting participants, so if you think you might qualify, consider reaching out for more information.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults aged ≥18 and ≤70 years, with symptoms such as upper abdominal pain or burning sensation, postprandial bloating, early satiety, etc., and who meet the diagnostic criteria for functional dyspepsia (FD) according to the Rome IV criteria.
• • Negative result on the C13 urea breath test, and no organic changes observed on gastroscopy.
• Exclusion Criteria:
• • Use of acid-suppressing drugs, prokinetic agents, antibiotic or anxiolytics within 4 weeks prior to enrollment.
• • History of abdominal surgery, abdominal or inflammatory bowel disease, diabetes, active psychiatric disorders, or severe diseases of vital organs such as the heart, lungs, liver, or kidneys.
• • Pregnant or breastfeeding participants, or those currently involved in other clinical research studies.